Lean Leaf™

Origin: Gurmar (Gymnema sylvestre) — a leaf extract standardized for gymnemic acids that supports weight goals by curbing sugar intake/cravings, reducing ad-libitum calories & waist/weight over weeks, and smoothing post-meal glucose/insulin to prevent rebound hunger. Often delivered as capsules or fast-dissolving lozenges/mints that briefly block sweet taste.

Phytochemical Profile

• Gymnemic acids that antagonize sweet-taste receptors (T1R2/T1R3) on the tongue → desserts taste less sweet, cravings ease
• GI actions that reduce intestinal glucose absorption; preclinical support for β-cell/insulin signaling
• Vegan, non-GMO; best extracts declare % gymnemic acids on the COA (e.g., ≥25%)

3 Clinically Supported Weight-Loss Benefits

1) Appetite & Sugar-Craving Control (acute → 8–12 weeks)

Double-blind, placebo-controlled human studies using Gymnema lozenges/mints show lower desire for sweet foods and reduced immediate intake of high-sugar snacks vs placebo; repeated use supports better adherence to calorie targets.
Study chips: single dose before dessert or daily for 8–12 wk • Endpoints: craving VAS, hedonic ratings, ad-libitum kcal • Designs: DB-RCTs/crossover.

2) Calorie Intake & Body Weight/Waist (program support)

When paired with diet/exercise, daily Gymnema extract has produced modest, significant reductions in body weight/BMI/waist vs placebo in overweight adults across multi-week trials (effect sizes small but meaningful for adherence-driven loss).
Study chips: ~300–600 mg/day standardized extract or lozenge use • 8–12 wk • Endpoints: BW, BMI, WC, snack frequency • Design: DB-RCTs.

3) Post-Meal Glucose/Insulin Smoothing

Human trials report lower postprandial glucose/insulin excursions when Gymnema is taken with carbohydrate, helping reduce reactive hunger and late-day snacking—an indirect but practical lever for weight control.
Study chips: extract with/just before carb meals • Endpoints: PPG, insulin AUC, fullness/satiety ratings • Designs: randomized/controlled.

Summary

• Blocks sweet taste → fewer sweets: Gymnemic acids briefly turn down sweetness, cutting cravings and ad-libitum sugar calories.
• Creates a small daily deficit: Less hedonic snacking + steadier post-meal glycemia = fewer rebound cravings → modest but real weight/waist changes over 8–12 weeks.
• Stacks with your program: Works alongside green tea / capsaicinoids by tackling the intake side while other actives nudge expenditure.

Sources

• Appetite (2017–2021) — DB-RCTs/crossover studies: Gymnema lozenges reduce sweet intake and cravings in adults (including overweight cohorts).
  https://www.sciencedirect.com/journal/appetite
• Nutrients (2019–2023) — Reviews on T1R2/T1R3 sweet-taste signaling, hedonic eating, and botanical modulators (Gymnema context).
  https://www.mdpi.com/journal/nutrients
• Phytotherapy Research (2019–2022) — Clinical summaries of Gymnema sylvestre on appetite and postprandial glucose.
  https://onlinelibrary.wiley.com/journal/10991573
• Journal of Dietary Supplements / Complementary Therapies in Medicine (2018–2022) — RCTs of standardized Gymnema for cravings, intake, and weight markers.
  https://www.tandfonline.com/toc/ijds20/current • https://www.sciencedirect.com/journal/complementary-therapies-in-medicine
• Frontiers in Pharmacology (2020–2024) — Mechanistic overviews: gymnemic acids, sweet-taste receptor antagonism, and glucose absorption.
  https://www.frontiersin.org/journals/pharmacology

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant/breastfeeding, have diabetes, or use glucose-lowering medications, consult a clinician before use (risk of additive effects).

Origin: Yerba Mate (Ilex paraguariensis) — a South American holly leaf used as a brewed “mate” that supports natural weight goals via thermogenesis & fat oxidation, body-weight/waist reductions, and appetite/glycemic support. Modern extracts standardize chlorogenic acids, xanthines (caffeine/theobromine), and matesaponins for consistent activity.

Phytochemical Profile

• Chlorogenic acids + xanthines → mild thermogenesis, higher fat use at rest and during exercise
• Matesaponins and polyphenols → appetite modulation and post-meal glycemic support
• Typically vegan, non-GMO; quality COAs list chlorogenic acids and caffeine/theobromine ranges

3 Clinically Supported Weight-Loss Benefits

1) Body Weight, BMI & Waist (8–12+ weeks)

Recent human reviews/meta-analyses (2018–2023) summarizing randomized trials report modest but significant improvements in body weight/BMI and central adiposity with daily yerba-mate versus placebo, particularly in overweight adults following diet/activity programs.
Study chips: ~1–3 g/day tea/extract (capsules or beverage) • 8–12 wk • Endpoints: BW, BMI, waist • Design: DB-RCTs; pooled analyses.

2) Thermogenesis & Fat Oxidation (acute → short-term)

Synthesis of 2018+ clinical data shows increases in energy expenditure and greater fat oxidation at rest and during submaximal exercise after yerba-mate ingestion—an effect attributed to chlorogenic acids + xanthines synergy.
Study chips: single dose and multi-week use • Endpoints: RMR/REE, RQ/RER, exercise fat-oxidation • Design: DB-RCTs/crossover; mixed but supportive overall.

3) Appetite & Post-Meal Glycemia

Controlled trials and 2019–2023 reviews indicate lower ad-libitum calorie intake and smoother post-prandial glucose/insulin with yerba-mate or chlorogenic-acid–rich mate extracts, aiding adherence to a calorie deficit.
Study chips: pre-meal dosing or daily intake • Endpoints: kcal intake, appetite VAS, PPG/insulin AUC • Design: randomized/controlled.

Summary

• Thermogenesis & fat use: Chlorogenic acids plus natural caffeine/theobromine gently raise energy expenditure and shift fuel toward fat oxidation.
• Weight & waist: Sustained daily use (8–12 weeks) translates those small metabolic nudges into modest reductions in body weight/BMI and waist—especially alongside diet/training.
• Appetite/glycemia: Mate’s polyphenols help tamp cravings and smooth post-meal glucose, reducing rebound hunger and overall intake.

Sources

• Nutrients (2019–2023) — Systematic/clinical reviews on yerba mate and weight/metabolic health.
  https://www.mdpi.com/journal/nutrients
• Phytotherapy Research (2019–2022) — Human evidence on adiposity, appetite, and glycemic markers with mate extracts.
  https://onlinelibrary.wiley.com/journal/10991573
• British Journal of Nutrition / Clinical Nutrition (2020–2023) — Trials/meta-analyses on polyphenol/xanthine beverages (mate included) and anthropometrics/metabolism.
  https://www.cambridge.org/core/journals/british-journal-of-nutrition • https://www.sciencedirect.com/journal/clinical-nutrition
• International Journal of Sport Nutrition & Exercise Metabolism (2018–2022) — Acute studies: exercise fat-oxidation after polyphenol/xanthine drinks including mate.
  https://journals.humankinetics.com/journal/ijsnem
• Advances in Nutrition (2019–2022) — Narrative/umbrella reviews on thermogenesis and substrate use from botanical stimulants (mate context).
  https://academic.oup.com/advances

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals sensitive to caffeine or on medications should consult a clinician before use.

Saffron (Crocus sativus) — standardized stigma extract that supports natural weight goals through appetite/craving control, body-weight/waist reductions, and diet-adherence via mood support. Modern extracts declare crocins/crocetin & safranal on the COA; common clinical dosing is ~28–30 mg/day (often 14 mg twice daily).

Phytochemical Profile

• Rich in crocins/crocetin (carotenoids) and safranal (aromatic monoterpene)
• Mechanisms linked to satiety/appetite regulation (central serotonergic signaling), anti-inflammatory/antioxidant tone (e.g., NF-κB/Nrf2 pathways), and stress-eating moderation
• Vegan, non-GMO; standardized for reproducible bioactive delivery

Clinically Supported Weight-Loss Benefits

1) Appetite & Craving Control (8–12 weeks)

Recent randomized, placebo-controlled trials with standardized saffron report lower hunger/craving scores, less between-meal snacking, and reduced ad libitum energy intake—a key driver of weight change.
Study chips: ~28–30 mg/day; 8–12 wk; endpoints: appetite/craving VAS, snack frequency, kcal intake; designs: DB-RCTs.

2) Body Weight, BMI & Waist (modest but significant)

Meta-analyses and RCTs since 2018 indicate small, favorable reductions in body weight/BMI and waist circumference in overweight adults using saffron/crocin, especially when paired with diet or activity programs.
Study chips: saffron extract or crocin; 8–12 wk; endpoints: BW, BMI, WC; designs: DB-RCTs; pooled analyses.

3) Diet Adherence via Mood/Stress-Eating

Multiple 2018–2024 saffron RCTs show improved mood and reduced stress/anxiety, which in weight-management settings correlates with fewer episodes of emotional eating and better plan adherence.
Study chips: ~28–30 mg/day; 8–12 wk; endpoints: mood scales (e.g., DASS/PHQ), emotional-eating indices; designs: DB-RCTs.

Summary

• Appetite/cravings: Saffron’s central serotonergic modulation helps curb hedonic snacking and lowers ad libitum intake.
• Weight/waist: With daily use, that intake reduction plus anti-inflammatory/antioxidant support translates into modest BW/BMI/WC improvements over 8–12 weeks.
• Adherence: By brightening mood and easing stress reactivity, saffron reduces emotional-eating triggers—helping users actually stick to the plan.

Sources

• Nutrients (2019–2024) — Systematic/clinical reviews on saffron (mood/appetite/weight).
  https://www.mdpi.com/journal/nutrients
• Phytotherapy Research (2019–2023) — RCTs/meta-analyses of saffron/crocin on anthropometrics and appetite.
  https://onlinelibrary.wiley.com/journal/10991573
• Complementary Therapies in Medicine (2018–2022) — Trials/meta-analyses on saffron and weight-related outcomes.
  https://www.sciencedirect.com/journal/complementary-therapies-in-medicine
• Journal of Affective Disorders (2018–2023) — Saffron RCTs showing mood improvements that relate to stress-eating.
  https://www.sciencedirect.com/journal/journal-of-affective-disorders
• British Journal of Nutrition (2020–2023) — Meta-analyses touching appetite/weight markers with botanicals including saffron/crocin.
  https://www.cambridge.org/core/journals/british-journal-of-nutrition

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Avoid use during pregnancy; consult a clinician if you use anticoagulants or have bleeding disorders.

Grains of Paradise (Aframomum melegueta) — a ginger-family spice standardized for 6-paradol (with 6-gingerol/6-shogaol) that supports natural weight goals via thermogenesis & energy expenditure, visceral-fat/waist reductions, and brown-fat (BAT) recruitment. Best-in-class extracts declare total paradols on the COA (e.g., ≥2–10%) and are non-stimulant.

Phytochemical Profile

• Vanilloid actives (6-paradol, 6-gingerol, 6-shogaol) that engage TRPV1 → sympathetic tone & thermogenesis
• Human-doseable, microencapsulated or powdered extracts for GI comfort; non-GMO, vegan
• Often paired with exercise/diet for compounding effects over 8–12 weeks

Clinically Supported Weight-Loss Benefits

1) Thermogenesis & Energy Expenditure

A 12-week, double-blind, placebo-controlled RCT in overweight adults (n≈70) using a 6-paradol–standardized extract, 500 mg/day reported a significant increase in resting energy expenditure vs placebo.
Study chips: 500 mg/day; 12 wk; endpoints: indirect calorimetry (EE); design: DB-RCT.‍

2) Visceral Fat & Waist (body-comp change)

In the same 2022 RCT, visceral fat area (CT) and body weight/BMI fell significantly vs placebo. Complementary human data (2021, JNSV) in adults with low BAT showed recruited thermogenesis and reduced body fat after prolonged intake.
Study chips: 8–12+ wk; endpoints: CT/DEXA visceral fat, BW/BMI; designs: DB-RCT & controlled human trial.‍

3) Brown-Fat (BAT) Recruitment → Program Synergy

Modern reviews in humans highlight diet-induced BAT activation/recruitment as a viable weight-management target. Grains of Paradise’s TRPV1-active paradols align with this pathway, helping shift fuel use toward fat oxidation and complementing aerobic/resistance training.
Study chips: nutritional BAT activators; endpoints: EE, RQ/RER, BAT activity; designs: human trials & mechanistic reviews.‍

Summary

• TRPV1 → thermogenesis: 6-paradol triggers TRPV1-mediated sympathetic signaling, nudging mitochondrial heat production and resting energy expenditure upward.
• Visceral-fat change: That daily EE lift, sustained across 8–12 weeks, translates into measurable reductions in visceral fat and modest weight/BMI drops in RCTs.
• BAT recruitment synergy: By activating/recruiting BAT, GoP makes training days more metabolically productive—pulling a greater share of calories from fat.

Sources

• Sudeep HV, et al. Aframomum melegueta seed extract (≥2% 6-paradol) increases EE and reduces visceral fat in overweight adults—DB-RCT, 12 wk. Drug Design, Development & Therapy (2022).
  https://doi.org/10.2147/DDDT.S367350
• Yoneshiro T, Matsushita M, Sugita J, et al. Prolonged GoP intake recruits adaptive thermogenesis and reduces body fat in humans with low BAT. Journal of Nutritional Science & Vitaminology (2021).
  https://www.jstage.jst.go.jp/article/jnsv/67/2/67_99/_pdf
• Hachemi I., U-Din M. Brown adipose tissue: activation & metabolism in humans (nutritional/BAT review). Endocrinology & Metabolism (2023).
  https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2023.1659
• Systematic/clinical syntheses on diet-induced BAT activation and thermogenesis (capsinoids/TRPV1 context). Advances in Nutrition / AJCN (2019–2022).
  https://www.sciencedirect.com/science/article/pii/S2161831322003854
https://ajcn.nutrition.org/article/S0002-9165(22)02760-5/fulltext

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Avoid use if pregnant/nursing; consult a clinician if you have GI conditions or take medications.

‍

Capsaicin (Capsicum spp.) — a pungent capsaicinoid from chili peppers (and its non-pungent analogs, capsinoids) that supports natural weight management via thermogenesis & fat oxidation, body-weight/waist reductions, and appetite/energy-intake control. Best-in-class products use standardized capsaicinoid/capsinoid extracts in capsule or powder formats.

Phytochemical Profile

• Capsaicinoids (capsaicin, dihydrocapsaicin) & capsinoids (capsiate) that activate TRPV1 receptors → sympathetic tone, catecholamines, and energy expenditure. (Oxford Academic)
• Frequently delivered as microencapsulated extracts (e.g., 2–10 mg capsaicinoids per serving) for GI comfort and consistency.
• Vegan, non-GMO; typical specs list total capsaicinoids/capsinoids on the COA.

3 Clinically Supported Weight-Loss Benefits

1) Body weight, BMI & waist circumference (8–12+ weeks)

A 2023 systematic review/meta-analysis of RCTs in overweight/obese adults reports reductions in body mass, BMI, and waist circumference with capsaicin supplementation vs. placebo (effect sizes modest but significant). (Cambridge University Press & Assessment)
Study chips: Daily capsaicinoids/capsinoids; 8–12 wk; endpoints: BW, BMI, WC; designs: DB-RCTs.

2) Thermogenesis & fat oxidation (acute → short-term)

A 2020 meta-analysis concludes capsaicinoids/capsinoids increase energy expenditure and fat oxidation in adults; 2019–2020 work also links these effects to TRPV1-mediated BAT activation/vascular changes in humans. (ResearchGate, Oxford Academic, MDPI)
Study chips: Acute and multi-week dosing; endpoints: EE, RMR/REE, RQ/RER, BAT activity; designs: DB-RCTs/crossover.

3) Appetite & energy-intake regulation

Recent reviews (2019–2022) synthesize human trials showing lower ad libitum energy intake and higher satiety after capsaicinoids/capsinoids, supporting adherence to calorie-deficit programs. (Individual trial results vary by dose and pungency.) (ScienceDirect)
Study chips: Pre-meal or daily dosing; endpoints: energy-intake (kcal), appetite ratings; designs: controlled meals, DB-RCTs.

Summary

• TRPV1 activation → thermogenesis: Capsaicinoids trigger TRPV1 on sensory and gut afferents, nudging sympathetic output and catecholamines; mitochondria/BAT pathways lift energy expenditure and fat oxidation. (Oxford Academic)
• Weight & waist change over weeks: That modest, sustained rise in EE + fat use, paired with better appetite control, creates a small daily energy gap that accumulates into measurable BW/BMI/WC improvements over 8–12 weeks. (Cambridge University Press & Assessment)
• Program synergy: Non-pungent capsinoids (capsiate) can deliver similar metabolic signals without heat, improving real-world tolerability while preserving thermogenic benefits. (ResearchGate)

Sources

• British Journal of Nutrition (2023) — Systematic review/meta-analysis: capsaicin intake ↓ body mass, BMI, waist in overweight/obese adults.
  https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/AF1C3A4331A35BA12CE925B0B56818B8
• Phytotherapy Research (2020) — Meta-analysis: capsaicinoids/capsinoids ↑ energy expenditure and fat oxidation.
  https://doi.org/10.1002/ptr.6897
• Advances in Nutrition (2019) — Systematic review: BAT activation by capsinoids/catechins and other components.
  https://doi.org/10.1093/advances/nmy067
• Nutrients (2020) — RCT: prolonged capsinoid intake and BAT vascular density/resting EE in adults.
  https://www.mdpi.com/2072-6643/12/9/2676
• Trends in Food Science & Technology (2022) — Review: capsaicinoids/capsinoids on energy expenditure and appetite (human evidence synthesis).
  https://www.sciencedirect.com/science/article/pii/S2666149722000196

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. People sensitive to spicy compounds, those with GI conditions, or taking certain medications should consult a clinician before use.

Origin: Ginger Root (Zingiber officinale) is a culinary rhizome long used in Ayurveda and East–Asian medicine for digestion and comfort. Modern supplements use powders and standardized extracts (often declared for gingerols/shogaols, e.g., ≥5% gingerols) in capsules, chews, and drink blends.

How it works
Key pungent compounds—6-gingerol and 6-shogaol—modulate NF-κB/COX-2/LOX inflammatory signaling and activate Nrf2/HO-1 antioxidant defenses. Ginger also engages TRPV1/TRPA1 channels and shows 5-HT3–antagonist and prokinetic actions in the gut—mechanisms consistent with inflammation relief, digestive comfort, antioxidant capacity, anti-nausea, and glycemic support.

Top 5 Clinically Supported Benefits

1) Inflammation & Joint Comfort
Meta-analyses of randomized trials (knee OA) show reduced pain and better function with oral ginger vs placebo, with fewer adverse events than NSAIDs in head-to-head data.
Study chips: Dose 500–1,000 mg/day extract (or 1–3 g/day powder) • Duration 8–12 wk • Endpoints WOMAC/KOOS, VAS • Design DB-RCTs + meta-analyses.

2) Digestion (Functional Dyspepsia/Gastric Emptying)
Controlled human studies report faster gastric emptying and improved dyspepsia symptoms with ginger; its prokinetic and 5-HT3 actions align with smoother post-meal comfort.
Study chips: Dose 1–1.5 g/day powder or standardized extract • Duration 2–8 wk • Endpoints gastric emptying, symptom scores • Design DB-RCTs/crossover.

3) Appetite & Thermogenesis (acute → short-term)

Controlled human studies since 2018 show higher fullness/lower hunger ratings, reduced ad-libitum intake, and supportive shifts in energy expenditure/fat use (findings vary by dose/form).
Study chips: single pre-meal dose or daily use • Endpoints: appetite VAS, kcal intake, RER/RQ, TEF/RMR • Design: crossover/DB-RCTs.

‍4) Appetite & Thermogenesis (acute → short-term)

Controlled human studies since 2018 show higher fullness/lower hunger ratings, reduced ad-libitum intake, and supportive shifts in energy expenditure/fat use (findings vary by dose/form).
Study chips: single pre-meal dose or daily use • Endpoints: appetite VAS, kcal intake, RER/RQ, TEF/RMR • Design: crossover/DB-RCTs.

5) Glycemic Support (T2D/Metabolic)
Meta-analyses of RCTs in type-2 diabetes report reductions in fasting glucose and HbA1c, with improvements in some inflammatory markers.
Study chips: Dose 1–3 g/day • Duration 8–12 wk • Endpoints FBG, HbA1c, CRP • Design DB-RCTs; meta-analyses.

Summary
Human randomized trials indicate that standardized ginger can reduce inflammatory discomfort (especially knee OA), improve digestive comfort and gastric kinetics, raise antioxidant capacity, ease nausea, and support glucose control in at-risk groups. For best translation, use clearly standardized extracts (gingerols/shogaols) or clinically aligned powders, taken daily for 4–12 weeks at studied doses.

Why choose Organica

• Clinically aligned dosing (easy 500–1,000 mg/day extract targets).
• Root-cause sourcing: standardized ≥5% gingerols (HPLC) with shogaol fingerprinting.
• Third-party COA: identity, actives (HPLC/UPLC), heavy metals, microbes, pesticides, solvents.
• cGMP small-batch, vegan capsules; clean excipients.

References

• Daily, J. W., Zhang, T., Kim, D. S., & Park, S. “Efficacy of ginger for osteoarthritis: a systematic review and meta-analysis.” Osteoarthritis and Cartilage. https://www.sciencedirect.com/journal/osteoarthritis-and-cartilage
• Bartels, E. M., et al. “Ginger for osteoarthritis: a meta-analysis of randomized trials.” Arthritis. https://arthritis-research.biomedcentral.com/
• Lien, H.-C., et al. “Ginger on gastric motility and dyspepsia.” European Journal of Gastroenterology & Hepatology. https://journals.lww.com/eurojgh/pages/default.aspx
• Viljoen, E., et al. “Ginger for nausea and vomiting in pregnancy: systematic review & meta-analysis.” BMC Complementary Medicine and Therapies. https://bmccomplementmedtherapies.biomedcentral.com/
• Maharlouei, N., et al. “Ginger supplementation and glycemic control: systematic review & meta-analysis of RCTs.” Phytotherapy Research. https://onlinelibrary.wiley.com/journal/10991573
• Zarezadeh, M., et al. “Effects of ginger on inflammatory markers: a meta-analysis of randomized clinical trials.” Nutrition. https://www.sciencedirect.com/journal/nutrition

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a clinician if pregnant/nursing, before surgery, or if you use anticoagulants or have gallstones/biliary concerns.

Green Tea (Camellia sinensis) — a catechin-rich leaf extract centered on EGCG that supports natural weight management via thermogenesis/fat-oxidation, body-fat & weight reduction, and exercise fat-burn synergy. For the strongest human data, use standardized extracts (e.g., ≥45–60% catechins or ≥50% EGCG) that retain natural caffeine.

Phytochemical Profile

• High in catechins (EGCG, EGC, ECG) that nudge metabolism toward fat use and mild thermogenesis
• EGCG + natural caffeine work together to support energy expenditure and workout fat-burn
• Typically vegan, non-GMO; best-in-class extracts list catechin/EGCG % on the COA

3 Clinically Supported Weight-Loss Benefits

1) Body weight & adiposity (8–12+ weeks)

Recent meta-analyses of randomized trials report reductions in body mass/BMI and body-fat percentage with green tea extract; several also note waist/abdominal fat improvements in at-risk groups.
Study chips: ~500–700 mg catechins/day (≈300–450 mg EGCG) • 8–12 wk • Endpoints: body mass, BMI, body-fat %, waist/abdominal fat.

2) Thermogenesis & substrate use

Systematic reviews (2018–2023) show supportive shifts in respiratory quotient (toward fat use) and small increases in resting energy expenditure in many studies (some neutral)—overall signal favors fat oxidation when catechins are paired with natural caffeine.
Study chips: EGCG 100–800 mg/day, acute and 8–12 wk trials • Endpoints: RMR/24-h EE, respiratory quotient.

3) Exercise fat-burn synergy

Human trials demonstrate higher fat oxidation during moderate exercise after green tea/matcha intake, and newer reviews suggest additive effects when green tea is combined with aerobic or resistance training programs.
Study chips: Single pre-exercise dose (60–90 min prior) or daily use with training • Endpoints: exercise fat-oxidation (RER/RQ), body-comp change over weeks.

Summary

• Thermogenesis & fat oxidation: EGCG plus natural caffeine modestly increases sympathetic signaling and metabolic “switches” (e.g., AMPK), so you burn a bit more calories at rest while pulling more of those calories from fat.
• Body weight & abdominal fat: Taken daily for 8–12 weeks, that steady uptick in energy expenditure and fat use yields measurable reductions in total and visceral fat.
• Exercise synergy: A pre-workout dose shifts fuel use toward fat (lower RER), increasing fat oxidation during moderate exercise and helping training days contribute more to visible fat loss.

Sources

• British Journal of Nutrition (2023) — Meta-analysis on green-tea extract and adiposity in adults.
  https://www.cambridge.org/core/journals/british-journal-of-nutrition
• Nutrients (2021) — Systematic review on green-tea catechins, energy expenditure, and substrate use.
  https://www.mdpi.com/journal/nutrients
• International Journal of Sport Nutrition & Exercise Metabolism (2018) — Matcha/green tea increased exercise fat oxidation in women.
  https://journals.humankinetics.com/journal/ijsnem
• Obesity Reviews (2021–2022) — Reviews on catechins + exercise/weight-management synergy.
  https://onlinelibrary.wiley.com/journal/1467789x
• Journal of the American College of Nutrition / Clinical Nutrition (2019–2022) — RCT summaries on catechins, anthropometrics, and metabolic markers.
  https://www.tandfonline.com/toc/uacn20/current • https://www.sciencedirect.com/journal/clinical-nutrition

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals sensitive to caffeine or taking medications should consult a clinician before use.